Policy & Regulation
RegeneRx Biopharmaceuticals likely to complete phase three clinical trial for dry eye syndrome in November 2020
15 October 2020 -

RegeneRx Biopharmaceuticals Inc (OTCQB: RGRX), a clinical-stage drug development company, is likely to complete its phase three clinical trial of RGN-259 for dry eye syndrome (ARISE-3) in November 2020, it was reported on Wednesday.

The company had enrolled 700 patients in the trial. The estimated study completion date and collection of data for the primary and secondary result measures will be in December, 2020.

J J Finkelstein, president and chief executive, said, 'We are pleased ARISE-3 is near completion, despite the challenges posed by the COVID-19 pandemic. This phase 3 trial is a critical milestone in the development of RGN-259 for dry eye syndrome and crucial to our future success. We look forward to announcing top line results as soon as practicable upon completion of the trial.'



Related Headlines